Saw nothing but funneling money back into their pr
Post# of 153935
(Total Views: 673)
Posted On: 09/21/2021 10:48:04 PM
Saw nothing but funneling money back into their private company, since they will use their patients which would put us shareholders at expense. Presenting an old paper indicates they will likely use their patent so us SHs can lose even more.
Saw a BOD that didn’t even agree with each other’s science (where is the synergy?)
I think the overall plan CytoDyn has, is to just get it for EUA and submit a BLA on OCT 15th so we could use it off label is better.
There is no reason an academic institution would steal our IP if we have it in writing that they can’t.
As SK said, there’s plenty of ways to write a contract. Right now, CytoDyn has a signed contract with an academic institution for Cancer. The others don’t even have a CEO.
Overall, I got bored and walked away with more questions that I don’t ever care to be answered.
It’s quite clear to me that they’re spreading their calls and SEC filings to put downward pressure on CytoDyns efforts.
Brazil Critical critical will be a success.
Todays PR is finally letting the world know what LONGS already knew.
“Scott Kelly to Present at the World Antiviral Congress 2021”
Slowly but surely, shorts are wrong.
“No sales in Philippines”, we are getting larger orders.
“Brazil trials won’t start”, they got approved.
“Brazil IV bag problem won’t be solved”
Then we got Critical approved.
They’re going to use “trials will take forever to fill” (even though there’s many cases a day there).
They’re going to use “those countries money situations won’t bring much revenue” but what’s funny is that Einstein has ran more Covid Trials than just about anyone. They also designed the trial with Recknor after having all the data.
The UK, Canada, US, the world is waiting.
Supply is low and Demand will be high.
Saw a BOD that didn’t even agree with each other’s science (where is the synergy?)
I think the overall plan CytoDyn has, is to just get it for EUA and submit a BLA on OCT 15th so we could use it off label is better.
There is no reason an academic institution would steal our IP if we have it in writing that they can’t.
As SK said, there’s plenty of ways to write a contract. Right now, CytoDyn has a signed contract with an academic institution for Cancer. The others don’t even have a CEO.
Overall, I got bored and walked away with more questions that I don’t ever care to be answered.
It’s quite clear to me that they’re spreading their calls and SEC filings to put downward pressure on CytoDyns efforts.
Brazil Critical critical will be a success.
Todays PR is finally letting the world know what LONGS already knew.
“Scott Kelly to Present at the World Antiviral Congress 2021”
Slowly but surely, shorts are wrong.
“No sales in Philippines”, we are getting larger orders.
“Brazil trials won’t start”, they got approved.
“Brazil IV bag problem won’t be solved”
Then we got Critical approved.
They’re going to use “trials will take forever to fill” (even though there’s many cases a day there).
They’re going to use “those countries money situations won’t bring much revenue” but what’s funny is that Einstein has ran more Covid Trials than just about anyone. They also designed the trial with Recknor after having all the data.
The UK, Canada, US, the world is waiting.
Supply is low and Demand will be high.
(22)
(0)